Cardiac defects, nuchal edema and abnormal lymphatic development are not associated with morphological changes in the ductus venosus by Burger, NB et al.
1 
 
1 
 
Title page Early Human Development 1 
Cardiac defects, nuchal edema and abnormal lymphatic development are not 2 
associated with morphological changes in the ductus venosus. 3 
 4 
Nicole B. Burger1 MD; Monique C. Haak2, MD, PhD; Evelien Kok3, Christianne J.M. 5 
de Groot1, MD, PhD; Weinian Shou4, PhD; Peter J. Scambler5, MD, PhD; Youngsook 6 
Lee6, PhD; Eunjin Cho6; Vincent M. Christoffels3, PhD; Mireille N. Bekker7, MD, PhD 7 
 8 
1 Department of Obstetrics and Gynecology, VU University Medical Center, De Boelelaan 1117 1081 HV 9 
Amsterdam, the Netherlands; N.B. Burger, n.burger@vumc.nl; C.J.M. de Groot, cj.degroot@vumc.nl 10 
2 Department of Obstetrics, Leiden University Medical Center, Albinusdreef 2 2333 ZA Leiden, the Netherlands; 11 
m.c.haak@lumc.nl 12 
3 Department of Anatomy, Embryology & Physiology, Academic Medical Center, Meibergdreef 9 1105 AZ 13 
Amsterdam, the Netherlands; E. Kok, e.kok0602@gmail.com; V.M. Christoffels, v.m.christoffels@amc.uva.nl 14 
4 Riley Heart Research Center, Herman B Wells Center for Pediatric Research, Division of Pediatric Cardiology, 15 
Indiana University School of Medicine, 705 Riley Hospital Dr. Indianapolis, Indiana, USA; wshou@iu.edu 16 
5 Department of Molecular Medicine, University College London, Institute of Child Health, Gower Street, London, 17 
WC1E 6BT, United Kingdom; p.scambler@ucl.ac.uk  18 
6 Department of Cell and Regenerative Biology, University of Wisconsin-Madison, 1111 Highland Ave. Madison, 19 
Wisconsin, USA; Y. Lee, youngsooklee@wisc.edu; E. Cho echo36@wisc.edu 20 
7 Department of Obstetrics and Gynecology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX 21 
Utrecht, the Netherlands; m.n.bekker-3@umcutrecht.nl 22 
 23 
Corresponding author: 24 
N.B. Burger, MD 25 
Department of Obstetrics and Gynecology, VU University Medical Center 26 
De Boelelaan 1117 1081 HV Amsterdam, the Netherlands 27 
Email: n.burger@vumc.nl  28 
2 
 
2 
 
Abstract  29 
Background: In human fetuses with cardiac defects and increased nuchal 30 
translucency, abnormal ductus venosus flow velocity waveforms are observed. It is 31 
unknown whether abnormal ductus venosus flow velocity waveforms in fetuses with 32 
increased nuchal translucency are a reflection of altered cardiac function or are 33 
caused by local morphological alterations in the ductus venosus.  34 
Aim: The aim of this study was to investigate if the observed increased nuchal 35 
translucency, cardiac defects and abnormal lymphatic development in the examined 36 
mouse models are associated with local changes in ductus venosus morphology. 37 
Study design: Mouse embryos with anomalous lymphatic development and nuchal 38 
edema (Ccbe1-/- embryos), mouse embryos with cardiac defects and nuchal edema 39 
(Fkbp12-/-, Tbx1-/-, Chd7fl/fl;Mesp1Cre, Jarid2-/-NE+ embryos) and mouse embryos with 40 
cardiac defects without nuchal edema (Tbx2-/-, Fgf10-/-, Jarid2-/-NE- embryos) were 41 
examined. Embryos were analyzed from embryonic day (E) 11.5 to 15.5 using markers 42 
for endothelium, smooth muscle actin, nerve tissue and elastic fibers.  43 
Results: All mutant and wild-type mouse embryos showed similar, positive endothelial 44 
and smooth muscle cell expression in the ductus venosus at E11.5-15.5. Nerve marker 45 
and elastic fiber expression were not identified in the ductus venosus in all investigated 46 
mutant and wild-type embryos. Local morphology and expression of the used markers 47 
were similar in the ductus venosus in all examined mutant and wild-type embryos.  48 
Conclusions: Cardiac defects, nuchal edema and abnormal lymphatic development 49 
are not associated with morphological changes in the ductus venosus. Ductus 50 
venosus flow velocity waveforms most probably reflect intracardiac pressure. 51 
 52 
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Introduction 55 
The ductus venosus is an embryonic shunt located at the level of the liver that 56 
connects the umbilical vein and the inferior vena cava [1;2]. The function of the ductus 57 
venosus is to transport well-oxygenated blood directly to the heart [1;2]. The narrowest 58 
part of the ductus venosus has been suggested to function as an active sphincter to 59 
regulate the extent of shunting [1;3;4]. This sphincter mechanism would ensure fetal 60 
adaptation to hypoxemia or stress. 61 
The phases of ductus venosus flow velocity waveforms correlate in timing to 62 
concurrent phases of the cardiac cycle [5]. Altered ductus venosus flow velocity 63 
waveforms may reflect changes in volume and pressure in the cardiac chambers [6]. 64 
Ductus venosus flow velocity waveforms are therefore considered to reflect cardiac 65 
function [6] and are utilized to assess the fetal hemodynamic performance.  66 
Ultrasound examination of the ductus venosus is increasingly used in daily prenatal 67 
obstetrical care [7;8]. Abnormal ductus venosus flow velocity waveforms in the first 68 
trimester of pregnancy are related to an increased risk for chromosomal abnormalities, 69 
cardiac defects, increased nuchal translucency (NT) and adverse pregnancy 70 
outcomes [2;8-16]. The causal mechanism of abnormal first-trimester ductus venosus 71 
flow velocity waveforms in fetuses with increased NT is unknown.  72 
Cardiac failure has been suggested to explain altered ductal flow velocity waveforms 73 
[2;9;10;14]. But abnormal ductal flow velocity waveforms can not be attributed to a 74 
specific cardiac defect that could influence the hemodynamic status [17;18]. Signs of 75 
fetal cardiac failure are rarely seen in fetuses with increased NT [19;20] and conflicting 76 
evidence on altered intracardiac velocities exists [21;22]. 77 
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Another theory to clarify abnormal ductus venosus flow velocity waveforms is a local 78 
morphological alteration in the ductus venosus. A morphological study of the ductus 79 
venosus in embryos with cardiac anomalies and nuchal edema, the morphological 80 
equivalent of increased NT, is currently lacking. We tested the hypothesis that nuchal 81 
edema, cardiac defects and abnormal lymphatic development are related to local 82 
changes in ductus venosus morphology, such as altered endothelial expression or 83 
disturbed contributions of smooth muscle cells, and histological construction of the 84 
ductus venosus tissue. The morphology of the ductus venosus was examined in three 85 
different categories of mutant mouse models; mouse embryos with (i) abnormal 86 
lymphatic development and nuchal edema, (ii) cardiac defects with nuchal edema and 87 
(iii) cardiac anomalies without nuchal edema.  88 
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Material and methods 89 
Embryos 90 
Mouse embryos were analyzed from embryonic day (E) 11.5 to 15.5. These embryonic 91 
stages coincide with initial lymphatic developmental processes and the presence of 92 
nuchal edema. Cardiovascular development is largely completed at E15.5. These 93 
embryonic stages correlate with the timing of the visibility of nuchal edema in human 94 
fetuses between 10 and 14 weeks gestational age. 95 
Different knockout and one knockdown mouse models were investigated and 96 
compared to wild-type (control) embryos (see Table 1). In the human clinical situation, 97 
increased NT is not related to a specific type of cardiac defect, but is associated with 98 
a spectrum of cardiac abnormalities. Therefore, multiple different mutant mouse 99 
models with lymphatic abnormalities or various cardiac defects with and without the 100 
presence of nuchal edema were studied.  101 
First, to examine the ductus venosus in mouse embryos with a lymphatic defect, 102 
Ccbe1-/- embryos [23] were analyzed. Ccbe1-/- embryos display absent lymphatic 103 
structures and increased nuchal thickening, as described earlier [23]. Second, to study 104 
the ductus venosus in various mouse models with cardiac malformations and nuchal 105 
edema, we have analyzed (i) Tbx1-/- embryos, showing abnormal development of the 106 
cardiac outflow tract, ventricular septal defects and aortic arch anomalies [24;25], (ii) 107 
Jarid2-/-NE+ embryos, displaying ventricular septal defects, non-compaction of the 108 
ventricular wall and double outlet right ventricle [26], (iii) Fkbp12-/- embryos showing 109 
myocardial non-compaction, large ventricular septal defects, hypertrophic trabeculae, 110 
deep intertrabecular recesses and thinner left ventricular wall [27] and (iv) 111 
Chd7fl/fl;Mesp1Cre embryos, demonstrating ventricular septal defects [28] and a 112 
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variety of pharyngeal arch artery defects [29]. Third, to investigate the ductus venosus 113 
in diverse mutant mouse models with heart anomalies but without the presence of 114 
nuchal edema, we have examined (i) Tbx2-/- embryos [30], showing enlarged and 115 
dilated ventricles, small endocardial cushions and outflow tract septation defects, such 116 
as double outlet right ventricle [31], (ii) Fgf10-/- embryos, displaying abnormal direction 117 
of the ventricular apex and absent pulmonary arteries and veins [32] and (iii) Jarid2-/-118 
NE- embryos [26], showing ventricular septal defects, non-compaction of the ventricular 119 
wall and double outlet right ventricle [26]. Jarid2-/- embryos showed nuchal edema in 120 
some embryos and normal nuchal thickness in other embryos. As a result, Jarid2-/- 121 
embryos with (Jarid2-/-NE+) and without (Jarid2-/-NE-) nuchal edema were examined in 122 
two different groups. The number of investigated embryos per mutant mouse model 123 
relied on availability. Because of limited availability we could not examine an equal 124 
number of the various mutant mouse models (see Table 1).  125 
Guidelines for care and use of mice, approved by the Department of Anatomy, 126 
Embryology & Physiology, Academic Medical Center (AMC), Amsterdam, the 127 
Netherlands, were followed. Mice were mated overnight and the day of the vaginal 128 
plug detection was established as E0.5. Embryos were isolated on E11.5-15.5 and 129 
fixed in 4% formaldehyde at 4°C overnight. Subsequently, embryos were dehydrated 130 
and the whole embryos were embedded in paraffin. Serial transverse sections of 7µm 131 
were made of the ductus venosus area, including all adjacent vessels. Every 5th 132 
section was mounted on a slide. The slides were dried at 37°C for at least 24 hours. 133 
 134 
Histological staining 135 
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Elastic fibers were visualized by Lawson van Gieson (LvG) staining. Deparaffinized 136 
slides were rinsed in bidistilled water, stained with Lawson (Klinipath) for 60 min and 137 
differentiated shortly in ethanol 96% for ± 10 seconds. Subsequently, slides were 138 
rinsed shortly in bidistilled water and stained in Van Gieson’s pichrofuchsin (5% 139 
fuchsin in 100ml picric acid with 0.25% hydrochloric acid) for ± 6 min. The slides were 140 
dehydrated rapidly through a graded series of ethanol and xylene, followed by 141 
mounting using Entellan (Merck). 142 
 143 
Antibodies 144 
An antibody for smooth muscle actin (SMA, mouse monoclonal antibody clone 1A4 145 
(1:4000), Sigma-Aldrich, St Louis, USA), for nerves (Ncam1 (Neural cell adhesion 146 
molecule 1); rabbit polyclonal antibody clone AB5032 (1:1500), Chemicon, Temecula, 147 
USA) and for endothelium (Pecam1 (Platelet endothelial cell adhesion molecule-1); 148 
goat polyclonal antibody clone SC-1506 (1:2000); Santa Cruz Biotechnology, Santa 149 
Cruz, USA) were used. 150 
 151 
Immunohistochemistry 152 
The slides were deparaffinated using a xylene to ethanol series. Inhibition of 153 
endogenous peroxidase activity was performed by incubating the slides in a solution 154 
of 0.3% H2O2 in PBS (phosphate buffered saline: 150 mM NaCl, 10 mM NaPi, pH 155 
7.4)/50% ethanol for 30 min. Next, the slides were rinsed twice in PBS for 5 min. In 156 
case of Pecam1, the slides were placed in 200ml 1% Antigen Unmasking solution 157 
(Vector Laboratories, Burlingame, USA) in a rack and cooked for 5 min at 1000 Watt 158 
in a high pressure cooker. The rack was cooled in bidistilled water and once the 159 
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pressure cooker was depressurized, the rack was placed on ice for ± 20 min. Next, 160 
the slides were rinsed in PBS for 5 min. 161 
All slides (SMA, Ncam1 and Pecam1) were blocked in Tris-sodium buffer (1M Tris, 162 
1.5M NaCl, adjusted to pH 7.4 using HCl) with 0.5% blocking reagent for 30 min. 163 
Subsequently, the slides were incubated overnight with the first specific antibody. The 164 
next day the slides were rinsed three times in TNT (0.1M Tris-HCl (pH 7.4), 0.15M 165 
NaCl, 0.05% Tween-20) for 5 min, followed by 30 min incubation with the second 166 
specific antibody in case of SMA and Ncam1 (Envision+ HRP anti-mouse or anti-167 
rabbit, respectively). In case of Pecam1, sections were incubated in biotinylated 168 
Donkey-anti-goat IgG (H+L) (Jackson ImmunoResearch Laboratories, #705065147, 169 
1:200) for 30 minutes. The slides were then rinsed three times in TNT, followed by 170 
incubation with Streptavidin-horseradish peroxidase (SA-HRP) (Dako, #P0397, 171 
1:100). All slides were rinsed three times with TNT followed by incubation in 172 
diaminobenzidine (DAB, Dako kit) for ± 5 min, depending on background staining 173 
intensity. The reaction was stopped in bidistilled water. Finally, all slides were 174 
counterstained using Mayer’s-Hematoxylin for 1 min. Subsequently, slides were rinsed 175 
in running tap water for ± 10 min and dehydrated quickly through a graded series of 176 
ethanol and xylene. To finish, sections were mounted using Entellan (Merck). All slides 177 
were analyzed by microscopy using Leica DFC 320.  178 
  179 
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Results 180 
Ductus venosus morphology is not changed by altered lymphatic development and 181 
nuchal edema (mouse model group I) 182 
A three dimensional view of the ductus venosus and its adjacent vessels is shown in 183 
a wild-type E15.5 mouse embryo in Figure 1. Ccbe1-/- embryos showed nuchal edema, 184 
whereas no nuchal edema was observed in wild-type embryos (see Figure 2). A single 185 
layer of smooth muscle actin (SMA) expression was identified in the ventral-caudal 186 
part of the ductus venosus in Ccbe1-/- and wild-type embryos. The dorsal-cranial part 187 
of the ductus venosus was slightly positive for SMA staining in all mutant and wild-188 
type embryos at E15.5. Similarly, single layered SMA expression was identified in 189 
other venous vessels, such as in the umbilical and portal vein and in the inferior vena 190 
cava. The endothelial surface of the ductus venosus showed equal, positive Pecam1 191 
staining along its entire length in all analyzed mutant embryos and wild-type embryos 192 
at E15.5. Ncam1 and LvG staining were absent in the ductus venosus in Ccbe1-/- and 193 
wild-type embryos at the examined stage (see Table 2 and Figure 2). 194 
 195 
Ductus venosus morphology is not affected by cardiac defects and nuchal edema 196 
(mouse model group II) 197 
Tbx1-/-, Jarid2-/-NE+, Fkbp12-/- and Chd7fl/fl;Mesp1Cre embryos all showed nuchal 198 
edema at E11.5-15.5 (see arrows in Figure 3). The ventral-caudal part of the ductus 199 
venosus showed similar, positive single-layered SMA expression in Tbx1-/-, Jarid2-/-200 
NE+, Fkbp12-/- and Chd7fl/fl;Mesp1Cre embryos and their wild-type embryos at E11.5-201 
15.5. Equally, slightly positive SMA staining was found in the dorsal-cranial part of the 202 
ductus venosus in all analyzed mutant and wild-type embryos at E11.5-15.5. Single-203 
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layered SMA expression was similarly expressed in other venous vessels. Similarly, 204 
positive expression of Pecam1 was observed in the entire ductus venosus in Tbx1-/-, 205 
Jarid2-/- NE+, Fkbp12-/- and Chd7fl/fl;Mesp1Cre embryos and their wild-type embryos in 206 
all analyzed stages. Ncam1 and LvG expression were absent in the ductus venosus 207 
in all examined mutant and wild-type embryos at E11.5-15.5 (see Table 2 and Figure 208 
3).  209 
 210 
Ductus venosus morphology is not altered by cardiac malformations without the 211 
presence of nuchal edema (mouse model group III) 212 
Nuchal edema was not observed in Tbx2-/-, Fgf10-/- or Jarid2-/-NE- embryos at E12.5-213 
14.5 (see Figure 4). The ventral-caudal part of the ductus venosus showed similar, 214 
positive, single-layered SMA expression in all examined mutant and wild-type embryos 215 
at the investigated stages. Slightly positive SMA expression was identified in the 216 
dorsal-cranial part of the ductus venosus in all investigated mutant and wild-type 217 
embryos at E12.5-14.5. Expression of single-layered SMA in the ductus venosus was 218 
similar in other venous vessels. The entire length of the ductus venosus showed 219 
similar and positive staining of the endothelium in Tbx2-/-, Fgf10-/- and Jarid2-/-NE- 220 
embryos and wild-type embryos at E12.5-14.5. Ncam1 and LvG staining were 221 
negative in the ductus venosus in all analyzed mutant and wild-type embryos at the 222 
investigated stages (see Table 2 and Figure 4). 223 
224 
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Discussion 225 
This is the first study that examined whether nuchal edema, cardiac defects and 226 
abnormal lymphatic development are associated with local changes in ductus venosus 227 
morphology. We demonstrated a similar expression of single-layered smooth muscle 228 
cells and endothelium and the absence of nerves and elastic fibers in the ductus 229 
venosus in various mouse models with cardiac and lymphatic defects, irrespective of 230 
the presence of nuchal edema. This study shows that the observed cardiac defects, 231 
nuchal edema and abnormal lymphatic development are not associated with 232 
morphological changes in the ductus venosus in the examined mouse models. Ductus 233 
venosus flow velocity waveforms therefore most probably reflect intracardiac 234 
pressure. 235 
Prior studies have reported on the strong relationship between abnormal first-trimester 236 
ductus venosus flow velocity waveforms, cardiac defects and increased NT [8;10-14]. 237 
The pathophysiological mechanism explaining this relationship is unknown. Abnormal 238 
endothelial differentiation is a mutual denominator in the development of both cardiac 239 
defects [33] and nuchal edema [34-37]. We examined whether a common process, 240 
such as an abnormal developmental process in the ductus venosus, is involved in this 241 
relationship. But no difference in expression of endothelium or any other used marker 242 
was found in the ductus venosus, independent of nuchal edema, lymphatic 243 
abnormalities or cardiac anatomy. The underlying cause that can explain the 244 
relationship between abnormal ductal flow velocity waveforms, cardiac defects and 245 
increased NT thus still awaits further investigation. 246 
Another suggested explanation for changed ductus venosus flow velocity waveforms 247 
is cardiac failure [2;9;10;14]. Altered ductus venosus flow velocity waveforms are not 248 
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related to a specific type of cardiac defect, neither is a higher pressure in the right 249 
ventricle responsible for changed ductus venosus flow velocity waveforms in human 250 
fetuses with increased NT [21]. Furthermore, the majority of cardiac malformations are 251 
not known to result in overt fetal cardiac failure [17;18]. Typical fetal findings upon 252 
cardiac failure, such as pericardial and pleural effusions, edema, ascites and 253 
cardiomegaly, are all absent. Abnormal ductal flow velocity waveforms have also been 254 
described in fetuses with increased NT as well as with normal NT, without a cardiac 255 
defect [19;38]. Cardiac failure due to a cardiac defect is therefore not responsible for 256 
altered flow velocity waveforms in the ductus venosus. 257 
We believe first-trimester hemodynamic alterations can explain changed ductal flow 258 
patterns. Major differences in cardiovascular function occur in the transition from early 259 
to late first-trimester pregnancy. In the first trimester of pregnancy the fetus is relatively 260 
impaired in diastolic function because of ventricular stiffness [39], increased cardiac 261 
afterload due to higher placental resistance [40] and fetal renal function has not yet 262 
developed to balance a possible hypervolemia [10]. A small disturbance in diastolic 263 
function may easily result in a hemodynamic imbalance in this phase of pregnancy. 264 
Diastolic function distinctly improves in the second and third trimester [10], peripheral 265 
vascular resistance decreases, cardiac compliance and output increase [41] and 266 
placental resistance reduces, which causes a fall in cardiac afterload [40]. These 267 
cardiac adaptations from early to late first-trimester pregnancy occur concomitantly 268 
with the disappearance of NT and match the time range of our analyses. Nuchal 269 
translucency is transient in nature and normally disappears around 14 weeks of human 270 
gestation [42]. A prior study has shown that increased NT is related to altered blood 271 
flow in the jugular vein and the ductus venosus [43]. It is possible that the local nuchal 272 
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edema is – in addition to the connection of the lymphatic system to the venous 273 
circulation – also drained through the lymphatic system by a correction of 274 
hemodynamic imbalance at the transition from early to late first-trimester pregnancy. 275 
Altered flow velocities in the jugular and ductal vein may also be explained by the fact 276 
that the accumulated fluid in the neck region might affect blood viscosity, which results 277 
in hemodynamic changes. Abnormal ductus venosus flow velocity waveforms are 278 
therefore possibly a secondary phenomenon to increased NT [20]. 279 
Altered first-trimester ductus venosus flow velocity waveforms are also associated with 280 
aneuploid fetuses with increased NT [9;22;44;45]. Prior studies in first-trimester 281 
trisomy 21 fetuses reported on abnormal cardiac function, specifically diastolic 282 
dysfunction, compared to fetuses with normal or increased NT, regardless of cardiac 283 
anatomy [22;46]. It was suggested that cardiac dysfunction could be attributed to 284 
hypervolemia [22]. Thus, these findings also direct toward the involvement of first-285 
trimester hemodynamic alterations in the origin of abnormal ductal flow patterns in 286 
aneuploid fetuses.  287 
The existence of a sphincter at the ductus venosus inlet remains contested [1;3;4;47-288 
49]. Again, we did not observe multiple smooth muscle cell layers or elastic fibers – 289 
features that are required to establish a contraction in a blood vessel – in the ductus 290 
venosus. The ductus venosus thus does not possess characteristics to function as a 291 
sphincter. Prior morphological studies in mouse and human embryos [48;49] showed 292 
similar results. Our findings are also in line with previous experimental studies in fetal 293 
sheep [50-53], reporting on relaxation or constriction of the total length of the ductus 294 
venosus, instead of a sphincter region.  295 
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We have examined a great diversity of different mouse models in this study. Although 296 
we did not observe different staining results in the mouse models as a group, it can 297 
not be excluded that if more embryos from a more uniform population were examined, 298 
some more subtle differences in for example SMA expression could be detected in the 299 
ductus venosus. 300 
Doppler assessment of the ductus venosus could not be performed in this study. The 301 
hypothesis of abnormal ductal patterns due to changed hemodynamics could therefore 302 
not be tested. Ultrasound examination of ductus venosus flow velocity waveforms 303 
could not be performed in the examined mouse models, because we were unable to 304 
study alive mouse embryos. Yet, an independent association between abnormal 305 
ductus venosus blood patterns and cardiac malformations has been demonstrated 306 
[10;12;13].  307 
In order to translate our findings in mouse models to the human situation further 308 
research on ductus venosus morphology in euploid and aneuploid human fetuses with 309 
increased NT is required. Preferentially, ductus venosus ultrasound assessment in 310 
human fetuses followed by morphological examination of the nuchal area, heart and 311 
ductus venosus is needed.  312 
In conclusion, this study shows that cardiac defects, nuchal edema and abnormal 313 
lymphatic development are not associated with morphological changes in the ductus 314 
venosus. Ductus venosus flow velocity waveforms therefore most probably reflect 315 
intracardiac pressure.  316 
  317 
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Figure legends 477 
Legend Figure 1: Three-dimensional view of the ductus venosus and its 478 
adjacent vessels. The black box represents the area that is shown in Figures 2-4. 479 
 480 
Legend Figure 2: Immunohistochemical analysis of the ductus venosus in 481 
mouse embryos with a lymphatic defect and nuchal edema (mouse model group 482 
I).  483 
Phenotype of Ccbe1+/+  control (a) and Ccbe1-/- (b) mouse embryos at E15.5. Note the 484 
nuchal edema in the Ccbe1-/- embryo (see arrow). Transverse sections of the ductus 485 
venosus (c-j). Pecam1, Platelet endothelial cell adhesion molecule-1; SMA, smooth 486 
muscle actin; Ncam1, Neural cell adhesion molecule 1; LvG, Lawson van Gieson. 487 
Scale bars represents 50 μm. 488 
 489 
Legend Figure 3: Immunohistochemical analysis of the ductus venosus in 490 
mouse embryos with a cardiac defect and nuchal edema (mouse model group 491 
II).  492 
Phenotype of Tbx1+/+ control (a), Tbx1-/- (b), Fkbp12+/+ control (c), Fkbp12-/- (d), 493 
Jarid2+/+ control (e), Jarid2-/-NE+ (f), Chd7+/+;Mesp1Cre control (g) and 494 
Chd7fl/fl;Mesp1Cre (h) embryos. Note the nuchal edema in all mutant embryos (see 495 
arrows). Transverse sections of the ductus venosus (i-oo). Pecam1, Platelet 496 
endothelial cell adhesion molecule-1; SMA, smooth muscle actin; Ncam1, Neural cell 497 
adhesion molecule 1; LvG, Lawson van Gieson. Scale bars represent 50 μm. 498 
 499 
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Legend Figure 4: Immunohistochemical analysis of the ductus venosus in 500 
mouse embryos with a cardiac defect without nuchal edema (mouse model 501 
group III).  502 
Phenotype of Tbx2+/+ control (a), Tbx2-/- (b), Fgf10+/+ control (c), Fgf10-/- (d), Jarid2+/+ 503 
control (e) and Jarid2-/-NE- (f) embryos. Note the absence of nuchal edema in all mutant 504 
embryos. Transverse sections of the ductus venosus (g-bb). Pecam1, Platelet 505 
endothelial cell adhesion molecule-1; SMA, smooth muscle actin; Ncam1, Neural cell 506 
adhesion molecule 1; LvG, Lawson van Gieson. Scale bars represents 50 μm. 507 
  508 
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Table legend 509 
Legend Table 2: 510 
+ positive staining; - absent staining; * positive staining at ventral-caudal part 511 
Pecam1, Platelet endothelial cell adhesion molecule-1; SMA, Smooth Muscle Actin;  512 
Ncam1, Neural cell adhesion molecule 1; LvG, Lawson van Gieson; IVC, inferior vena 513 
cava  514 
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Table 1: Number of mouse embryos examined per embryonic day 515 
516 
 Embryonic day Number of mouse embryos 
Mouse embryos with a lymphatic defect (mouse model group I) 
 
Ccbe1+/+ 15.5 4 
 
Ccbe1-/- 15.5 4 
Mouse embryos with a cardiac defect with nuchal edema (mouse model group II) 
 
Tbx1+/+ 14.5 2 
 
Tbx1-/- 14.5 3 
 
Fkbp12+/+ 11.5-13.5 5 
 
Fkbp12-/- 11.5-13.5 5 
 
Jarid2+/+ 14.0 1 
 
Jarid2-/- NE+ 14.0-14.5 4 
 
Chd7+/+ 15.5 2 
 
Chd7-/- 15.5 2 
Mouse embryos with a cardiac defect without nuchal edema (mouse model group III) 
 
Tbx2+/+ 12.5 3 
 
Tbx2-/- 12.5 3 
 
Fgf10+/+ 13.5 2 
 
Fgf10-/- 13.5 6 
 
Jarid2+/+ 14.5 1 
 
Jarid2-/- NE- 14.5 5 
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Table 2: Staining results of the ductus venosus in mouse embryos with lymphatic defects and nuchal edema, cardiac defects 517 
and nuchal edema and cardiac defects without nuchal edema  518 
Immunohistochemical and histological staining results in mouse embryos with:           
Lymphatic defects and nuchal edema  Cardiac defects and nuchal edema  Cardiac defects without nuchal edema 
                 
Ccbe1-/-  Pecam1 SMA LvG Ncam1  Tbx1-/-  Pecam1 SMA LvG Ncam1  Tbx2-/-  Pecam1 SMA LvG Ncam1 
ductus venosus +  +* - -  ductus venosus +  +* - -  ductus venosus +  +* - - 
pre-hepatic IVC + + - -  pre-hepatic IVC + + - -  pre-hepatic IVC + + - - 
post-hepatic IVC + + - -  post-hepatic IVC + + - -  post-hepatic IVC + + - - 
umbilical vein + + - -  umbilical vein + + - -  umbilical vein + + - - 
portal vein + + - -  portal vein + + - -  portal vein + + - - 
                 
Ccbe1+/+ control Pecam1 SMA LvG Ncam1  Tbx1+/+ control Pecam1 SMA LvG Ncam1  Tbx2+/+ control Pecam1 SMA LvG Ncam1 
ductus venosus +  +* - -  ductus venosus +  +* - -  ductus venosus +  +* - - 
pre-hepatic IVC + + - -  pre-hepatic IVC + + - -  pre-hepatic IVC + + - - 
post-hepatic IVC + + - -  post-hepatic IVC + + - -  post-hepatic IVC + + - - 
umbilical vein + + - -  umbilical vein + + - -  umbilical vein + + - - 
portal vein + + - -  portal vein + + - -  portal vein + + - - 
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      Jarid2-/-NE+ Pecam1 SMA LvG Ncam1  Fgf10-/-  Pecam1 SMA LvG Ncam1 
      ductus venosus +  +* - -  ductus venosus +  +* - - 
      pre-hepatic IVC + + - -  pre-hepatic IVC + + - - 
      post-hepatic IVC + + - -  post-hepatic IVC + + - - 
      umbilical vein + + - -  umbilical vein + + - - 
      portal vein + + - -  portal vein + + - - 
                 
      Jarid2+/+ control Pecam1 SMA LvG Ncam1  Fgf10+/+ control  Pecam1 SMA LvG Ncam1 
      ductus venosus +  +* - -  ductus venosus +  +* - - 
      pre-hepatic IVC + + - -  pre-hepatic IVC + + - - 
      post-hepatic IVC + + - -  post-hepatic IVC + + - - 
      umbilical vein + + - -  umbilical vein + + - - 
      portal vein + + - -  portal vein + + - - 
                 
      Fkbp12-/- Pecam1 SMA LvG Ncam1  Jarid2-/-NE- Pecam1 SMA LvG Ncam1 
      ductus venosus +  +* - -  ductus venosus +  +* - - 
      pre-hepatic IVC + + - -  pre-hepatic IVC + + - - 
      post-hepatic IVC + + - -  post-hepatic IVC + + - - 
      umbilical vein + + - -  umbilical vein + + - - 
      portal vein + + - -  portal vein + + - - 
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      Fkbp12+/+ control Pecam1 SMA LvG Ncam1  Jarid2+/+ control Pecam1 SMA LvG Ncam1 
      ductus venosus +  +* - -  ductus venosus +  +* - - 
      pre-hepatic IVC + + - -  pre-hepatic IVC + + - - 
      post-hepatic IVC + + - -  post-hepatic IVC + + - - 
      umbilical vein + + - -  umbilical vein + + - - 
      portal vein + + - -  portal vein + + - - 
                 
      Chd7fl/fl;Mesp1Cre Pecam1 SMA LvG Ncam1       
      ductus venosus +  +* - -       
      pre-hepatic IVC + + - -       
      post-hepatic IVC + + - -       
      umbilical vein + + - -       
      portal vein + + - -       
                 
      Chd7+/+;Mesp1Cre control Pecam1 SMA LvG Ncam1       
      ductus venosus +  +* - -       
      pre-hepatic IVC + + - -       
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      post-hepatic IVC + + - -       
      umbilical vein + + - -       
      portal vein + + - -       
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